Ricks told CNBC Wednesday that Lilly had held off on advertising Zepbound and launching the drug internationally in order to boost inventory in the U.S.: We havent been stimulating demand the way we had originally planned. Yet on the earnings call, Ricks maintained that underlying growth for the drugs was as strong as we would have hoped. Ricks asserted that Lilly management did not view the gap between the Q3 results and the projections of even higher growth as indicating a softening of demand for the GLP-1 drugs: Demand for Mounjaro and Zepbound has been strong and continues to grow as we expand both access and supply. Johnson denied that competition from compounders had a huge financial impact on Lillys business
Although Im still about 25 pounds away from goal, with the encouragement and motivation I continue to Lisa A., Age 55 15+ YEARS IN BUSINESS 10,000+ HAPPY CUSTOMERS 4.9 STARS FROM OUR CUSTOMERS Meet the Team
They are harder to digest, and when paired with the delayed gastric emptying caused by GLP-1 medications, they can lead to increased nausea, indigestion, and a feeling of fullness that lingers uncomfortably
May foster a healthier gut microbiota environment
In the report, the analysts predicted that Lilly and Novo will lower the prices of their products 10+% by 2027 in order to stay competitive and gain more health insurance coverage
13, 2023 University of Missouri Health Care has initiated its first treatment using an FDA-approved targeted radioactive medicine for advanced metastatic prostate cancer